- Home
- NAGE vs BBNX Comparison
NAGE vs BBNX Comparison
Compare NAGE & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | BBNX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 493.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | BBNX |
|---|---|---|
| Price | $4.86 | $10.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $16.00 | ★ $26.22 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.75 | $34.99 |
| Revenue Next Year | $19.96 | $34.47 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $8.89 |
| 52 Week High | $14.66 | $32.71 |
Technical Indicators
Market Signals| Indicator | NAGE | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 25.81 |
| Support Level | $4.73 | N/A |
| Resistance Level | $5.32 | $15.53 |
| Average True Range (ATR) | 0.28 | 0.70 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 11.37 | 20.75 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.